Cardior Announces First Patient Dosed in Phase 2 Study — Hadean Ventures Home Portfolio Team…
Continue Reading-
Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal
Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal — Hadean Ventures Home…
Continue Reading -
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan —…
Continue Reading -
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study…
Continue Reading -
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial — Hadean…
Continue Reading -
Galecto Announces Pricing of Initial Public Offering
Galecto Announces Pricing of Initial Public Offering — Hadean Ventures Home Portfolio Team Impact Investors…
Continue Reading -
Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli®
Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli® — Hadean Ventures Home Portfolio…
Continue Reading -
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study
Abliva doses the first patient in its KL1333 Phase Ia/b clinical study — Hadean Ventures…
Continue Reading -
Hadean Ventures invest in Galecto`s $64 million round equity financing
Hadean Ventures invest in Galecto`s $64 million round equity financing — Hadean Ventures Home Portfolio…
Continue Reading -
Ingrid Teigland Akay included in Business Insider’s list of 100 People Transforming Business in Europe.
Ingrid Teigland Akay included in Business Insider’s list of 100 People Transforming Business in Europe.…
Continue Reading